Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GMAB Genmab A/S	$21.88 -0.6%	$21.18	$17.24 ▼ $28.56	$14.12B	0.94	1.25 million shs	837,917 shs
ITCI Intra-Cellular Therapies	$131.87	$131.87	$70.90 ▼ $131.98	$14.05B	0.69	1.56 million shs	N/A
PCVX Vaxcyte	$36.21 -3.1%	$33.84	$27.66 ▼ $121.06	$4.82B	1.19	1.49 million shs	1.19 million shs
RDY Dr. Reddy's Laboratories	$14.48 -1.4%	$14.91	$12.26 ▼ $16.89	$12.26B	0.33	1.52 million shs	1.07 million shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GMAB Genmab A/S	+0.64%	+0.69%	-0.09%	+9.83%	-17.96%
ITCI Intra-Cellular Therapies	0.00%	0.00%	0.00%	0.00%	+72.36%
PCVX Vaxcyte	+2.19%	+3.12%	+11.09%	+21.92%	-54.07%
RDY Dr. Reddy's Laboratories	+0.49%	+0.40%	-3.44%	+7.44%	-6.58%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GMAB Genmab A/S	3.9187 of 5 stars	3.3	5.0	0.0	0.0	2.6	0.0	3.1
ITCI Intra-Cellular Therapies	0.9225 of 5 stars	1.1	0.0	0.0	4.5	1.3	1.7	0.6
PCVX Vaxcyte	1.8072 of 5 stars	3.6	1.0	0.0	0.0	2.5	1.7	0.0
RDY Dr. Reddy's Laboratories	2.7536 of 5 stars	2.5	4.0	1.7	0.0	2.0	0.0	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GMAB Genmab A/S	2.64	Moderate Buy	$37.80	72.76% Upside
ITCI Intra-Cellular Therapies	2.17	Hold	$109.70	-16.81% Downside
PCVX Vaxcyte	3.10	Buy	$136.50	276.97% Upside
RDY Dr. Reddy's Laboratories	3.00	Buy	$16.95	17.06% Upside

Current Analyst Ratings Breakdown

Latest PCVX, ITCI, GMAB, and RDY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/8/2025	GMAB Genmab A/S	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$45.00 ➝ $46.00
6/5/2025	RDY Dr. Reddy's Laboratories	Hsbc Global Res Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
6/5/2025	RDY Dr. Reddy's Laboratories	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$14.44 ➝ $16.90
4/22/2025	PCVX Vaxcyte	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight

(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GMAB Genmab A/S	$3.12B	4.50	$1.52 per share	14.42	$8.04 per share	2.72
ITCI Intra-Cellular Therapies	$680.50M	20.64	N/A	N/A	$6.15 per share	21.44
PCVX Vaxcyte	N/A	N/A	N/A	N/A	$26.52 per share	N/A
RDY Dr. Reddy's Laboratories	$3.81B	3.17	$1.02 per share	14.15	$4.73 per share	3.06

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GMAB Genmab A/S	$1.14B	$1.76	12.43	12.29	6.64	35.11%	18.08%	14.52%	8/14/2025 (Estimated)
ITCI Intra-Cellular Therapies	-$139.67M	-$0.73	N/A	694.05	N/A	-14.07%	-9.93%	-8.38%	N/A
PCVX Vaxcyte	-$463.93M	-$3.99	N/A	N/A	N/A	N/A	-17.12%	-16.26%	8/5/2025 (Estimated)
RDY Dr. Reddy's Laboratories	$663M	$0.66	21.94	17.66	5.18	17.38%	17.98%	12.24%	7/25/2025 (Estimated)

Latest PCVX, ITCI, GMAB, and RDY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	GMAB Genmab A/S	$0.39	N/A	N/A	N/A	N/A	N/A
8/5/2025	Q2 2025	PCVX Vaxcyte	-$1.12	N/A	N/A	N/A	N/A	N/A
7/25/2025	Q1 25/26	RDY Dr. Reddy's Laboratories	$0.19	N/A	N/A	N/A	$88.27 billion	N/A
5/14/2025	Q1 2025	PCVX Vaxcyte	-$1.02	-$1.04	-$0.02	-$1.04	N/A	N/A
5/9/2025	Q4 24/25	RDY Dr. Reddy's Laboratories	$0.20	$0.22	+$0.02	$0.22	$83.70 billion	$996.17 million
5/8/2025	Q1 2025	GMAB Genmab A/S	$0.23	$0.31	+$0.08	$0.31	$5.17 billion	$715.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GMAB Genmab A/S	N/A	N/A	N/A	N/A	N/A
ITCI Intra-Cellular Therapies	N/A	N/A	N/A	N/A	N/A
PCVX Vaxcyte	N/A	N/A	N/A	N/A	N/A
RDY Dr. Reddy's Laboratories	$0.08	0.55%	N/A	12.12%	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GMAB Genmab A/S	N/A	5.34	5.32
ITCI Intra-Cellular Therapies	N/A	7.66	7.51
PCVX Vaxcyte	N/A	17.70	17.70
RDY Dr. Reddy's Laboratories	0.02	1.92	1.37

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GMAB Genmab A/S	7.07%
ITCI Intra-Cellular Therapies	92.33%
PCVX Vaxcyte	96.78%
RDY Dr. Reddy's Laboratories	3.85%

Insider Ownership

Company	Insider Ownership
GMAB Genmab A/S	1.54%
ITCI Intra-Cellular Therapies	2.60%
PCVX Vaxcyte	3.10%
RDY Dr. Reddy's Laboratories	2.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GMAB Genmab A/S	2,682	641.54 million	631.66 million	Optionable
ITCI Intra-Cellular Therapies	560	106.52 million	103.56 million	Optionable
PCVX Vaxcyte	160	129.00 million	125.01 million	Optionable
RDY Dr. Reddy's Laboratories	27,811	834.90 million	818.20 million	Optionable

PCVX, ITCI, GMAB, and RDY Headlines

Recent News About These Companies

New Strong Sell Stocks for July 18th

July 18 at 6:11 AM | zacks.com

Dr. Reddy's Laboratories (RDY) Expected to Announce Earnings on Friday

July 18 at 2:14 AM | marketbeat.com

Dr. Reddy's Laboratories climbs Thursday, underperforms competitors

July 17 at 8:28 AM | marketwatch.com

Dr. Reddy’s Laboratories Ltd. (DRREDDY) Has a New Rating from Morgan Stanley

July 16 at 10:27 PM | theglobeandmail.com

Signaturefd LLC Cuts Stock Holdings in Dr. Reddy's Laboratories Ltd (NYSE:RDY)

July 16 at 5:38 AM | marketbeat.com

Ballentine Partners LLC Lowers Stock Position in Dr. Reddy's Laboratories Ltd (NYSE:RDY)

July 14, 2025 | marketbeat.com

Reviewing Supernus Pharmaceuticals (NASDAQ:SUPN) & Dr. Reddy's Laboratories (NYSE:RDY)

July 11, 2025 | americanbankingnews.com

Allspring Global Investments Holdings LLC Sells 439,622 Shares of Dr. Reddy's Laboratories Ltd (NYSE:RDY)

July 9, 2025 | marketbeat.com

RDY - Dr Reddy's Laboratories Ltd ADR Valuation - Morningstar

July 2, 2025 | morningstar.comM

RDY Dr. Reddy's Laboratories Limited - Seeking Alpha

July 2, 2025 | seekingalpha.com

Bessemer Group Inc. Purchases 81,024 Shares of Dr. Reddy's Laboratories Ltd (NYSE:RDY)

June 27, 2025 | marketbeat.com

Dr. Reddy's Laboratories slips Thursday, underperforms competitors

June 26, 2025 | marketwatch.com

Dr. Reddy's Laboratories Ltd (NYSE:RDY) Shares Sold by Robeco Institutional Asset Management B.V.

June 26, 2025 | marketbeat.com

Dr. Reddy's Laboratories slips Monday, still outperforms market

June 23, 2025 | marketwatch.com

Dr. Reddy's Laboratories Ltd (NYSE:RDY) Shares Sold by Ritholtz Wealth Management

June 19, 2025 | marketbeat.com

Dr. Reddy's Laboratories rallies Tuesday, outperforms competitors

June 10, 2025 | marketwatch.com

Dr. Reddy's Laboratories Reaches Analyst Target Price

June 8, 2025 | nasdaq.com

HSBC Upgrades Dr. Reddy's Laboratories Limited - Depositary Receipt () (RDY)

June 6, 2025 | msn.com

HSBC Upgrades Dr. Reddy’s Laboratories Limited (RDY) to Buy from Hold

June 5, 2025 | msn.com

Dr. Reddy's Laboratories rallies Thursday, outperforms competitors

June 5, 2025 | marketwatch.com

HSBC upgrades Dr Reddy’s on weight loss drug semaglutide-driven earnings rebound

June 5, 2025 | in.investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PCVX, ITCI, GMAB, and RDY Company Descriptions

Genmab A/S NASDAQ:GMAB

$21.88 -0.13 (-0.59%)

Closing price 04:00 PM Eastern

Extended Trading

$21.92 +0.05 (+0.21%)

As of 07:11 PM Eastern

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Intra-Cellular Therapies NASDAQ:ITCI

Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.

Vaxcyte NASDAQ:PCVX

$36.21 -1.16 (-3.10%)

Closing price 04:00 PM Eastern

Extended Trading

$36.25 +0.04 (+0.11%)

As of 04:42 PM Eastern

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

Dr. Reddy's Laboratories NYSE:RDY

$14.48 -0.21 (-1.43%)

Closing price 03:59 PM Eastern

Extended Trading

$14.64 +0.16 (+1.10%)

As of 05:52 PM Eastern

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time